Tag: Gabapentin enacarbil

According to official FDA labeling, the pill with the imprint **GS TF7** is identified as Horizant (gabapentin enacarbil) 300 mg. This extended-release medication is prescribed for adults to treat certain neurological conditions, specifically restless legs syndrome and postherpetic neuralgia.

Affecting an estimated 5% to 10% of adults in the U.S., Restless Leg Syndrome (RLS) is a common neurological disorder. For those with moderate to severe symptoms, the question often arises: **is gabapentin good for restless leg syndrome?** This medication has emerged as a key treatment option.

Restless Legs Syndrome (RLS) affects an estimated 5 to 10 percent of adults in the United States [1.6.1]. For those prescribed Horizant to manage RLS or postherpetic neuralgia, the question of 'How does Horizant make you feel?' is critical. Experiences can range widely.

While standard gabapentin is not a prodrug, a modified version called gabapentin enacarbil (Horizant) was specifically designed as one to improve the drug's bioavailability. This distinction is critical for understanding the different pharmacokinetic profiles and clinical applications of these related medications. The initial formulation faces limitations in oral absorption that the prodrug was engineered to overcome.

The U.S. Food and Drug Administration (FDA) approved HORIZANT (gabapentin enacarbil) for restless legs syndrome (RLS) in 2011 and for postherpetic neuralgia (PHN) in 2012. This extended-release medication offers a unique approach to managing these nerve-related conditions, but **what is HORIZANT used for** specifically and how does it differ from other treatments?.